drugset

drugset / Trial / NCT06021210

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

NCT06021210 ↗

Phase 2 Unknown 80 enrolled The First Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Timeline

Start: 2022-07-07
Primary completion: 2024-07-01
Completion: 2025-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Letermovir	Small molecule	—	—

Indications